Universal influenza vaccines: Shifting to better vaccines
暂无分享,去创建一个
J. Donnelly | Francesco Berlanda Scorza | V. Tsvetnitsky | John J. Donnelly | Francesco Berlanda Scorza | Vadim Tsvetnitsky | Francesco Berlanda Scorza
[1] R. Compans,et al. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. , 2013, Molecular Therapy.
[2] David N. Taylor,et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. , 2011, Vaccine.
[3] J. Shiver,et al. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. , 2009, Vaccine.
[4] A. Fauci,et al. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine , 2010, Nature Medicine.
[5] P. Palese,et al. Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. , 2015, Current topics in microbiology and immunology.
[6] D. Baltimore,et al. Broad protection against influenza infection by vectored immunoprophylaxis in mice , 2013, Nature Biotechnology.
[7] B. Futcher,et al. Deliberate reduction of hemagglutinin and neuraminidase expression of influenza virus leads to an ultraprotective live vaccine in mice , 2013, Proceedings of the National Academy of Sciences.
[8] A. Jegerlehner,et al. Universal vaccine against influenza virus: Linking TLR signaling to anti‐viral protection , 2012, European journal of immunology.
[9] D. Skowronski,et al. Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine. , 2013, Vaccine.
[10] Mustafizur Rahman,et al. Influenza is a Major Contributor to Childhood Pneumonia in a Tropical Developing Country , 2010, The Pediatric infectious disease journal.
[11] R. Cortese,et al. Vaccination to Conserved Influenza Antigens in Mice Using a Novel Simian Adenovirus Vector, PanAd3, Derived from the Bonobo Pan paniscus , 2013, PloS one.
[12] G. Wong,et al. Intranasal Antibody Gene Transfer in Mice and Ferrets Elicits Broad Protection Against Pandemic Influenza , 2013, Science Translational Medicine.
[13] D. G. Gibson,et al. Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice , 2013, Emerging Microbes & Infections.
[14] Harish Nair,et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis , 2011, The Lancet.
[15] D. Pérez,et al. Influenza Viruses with Rearranged Genomes as Live-Attenuated Vaccines , 2013, Journal of Virology.
[16] S. Himanen,et al. AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland , 2012, PloS one.
[17] J. Chan,et al. Cytotoxic T Cells Are the Predominant Players Providing Cross-Protective Immunity Induced by γ-Irradiated Influenza A Viruses , 2010, Journal of Virology.
[18] Xuguang Li,et al. Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes , 2014, Mucosal Immunology.
[19] R. Rappuoli,et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. , 2006, Vaccine.
[20] J. Whittle,et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies , 2013, Nature.
[21] Ying-hua Chen,et al. N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication , 2003, FEMS Immunology and Medical Microbiology.
[22] W. Fiers,et al. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. , 2008, Vaccine.
[23] Brian Chin,et al. Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918–20 pandemic: a quantitative analysis , 2006, The Lancet.
[24] hristine B. Turleya,et al. afety and immunogenicity of a recombinant M 2 e – flagellin influenza vaccine STF 2 . 4 xM 2 e ) in healthy adults , 2011 .
[25] R. Compans,et al. Virus-like Particles Containing Multiple M2 Extracellular Domains Confer Improved Cross-protection Against Various Subtypes of Influenza Virus. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[26] J. Skehel,et al. A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins , 2011, Science.
[27] J. Katz,et al. Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: a Phase 1 dose-escalation study in healthy adults. , 2014, Vaccine.
[28] J. Mascola,et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection , 2015, Nature Medicine.
[29] M. Wolzt,et al. Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1. , 2013, Vaccine.
[30] T. Schlake,et al. A novel, disruptive vaccination technology , 2013, Human vaccines & immunotherapeutics.
[31] J. Langley,et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. , 2010, The Journal of infectious diseases.
[32] N. S. Laursen,et al. Highly Conserved Protective Epitopes on Influenza B Viruses , 2012, Science.
[33] W. Fiers,et al. An Influenza A Vaccine Based on Tetrameric Ectodomain of Matrix Protein 2* , 2008, Journal of Biological Chemistry.
[34] G. Rimmelzwaan,et al. Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases , 2014, Viruses.
[35] T. Ben-Yedidia,et al. Priming by a novel universal influenza vaccine (Multimeric-001)-a gateway for improving immune response in the elderly population. , 2014, Vaccine.
[36] N. Sardesai,et al. Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine. , 2014, Vaccine.
[37] Caitlin E. Mullarkey,et al. Immunity Against Heterosubtypic Influenza Virus Induced By Adenovirus And MVA Expressing Nucleoprotein And Matrix Protein-1 , 2013, Scientific Reports.
[38] T. Ross,et al. Cocktail of H5N1 COBRA HA vaccines elicit protective antibodies against H5N1 viruses from multiple clades , 2015, Human vaccines & immunotherapeutics.
[39] G. Stoloff,et al. Synthetic multi‐epitope peptides identified in silico induce protective immunity against multiple influenza serotypes , 2007, European journal of immunology.
[40] H. Jin,et al. A Single Amino Acid in the Stalk Region of the H1N1pdm Influenza Virus HA Protein Affects Viral Fusion, Stability and Infectivity , 2014, PLoS pathogens.
[41] Adrian Apetri,et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen , 2015, Science.
[42] W. Fiers,et al. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. , 2008, Vaccine.
[43] K. Broman,et al. Modified Vaccinia Virus Ankara Encoding Influenza Virus Hemagglutinin Induces Heterosubtypic Immunity in Macaques , 2014, Journal of Virology.
[44] R. Cox,et al. An H7N1 Influenza Virus Vaccine Induces Broadly Reactive Antibody Responses against H7N9 in Humans , 2014, Clinical and Vaccine Immunology.
[45] Z. Xiang,et al. A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[46] P. Palese,et al. Vaccination with Adjuvanted Recombinant Neuraminidase Induces Broad Heterologous, but Not Heterosubtypic, Cross-Protection against Influenza Virus Infection in Mice , 2015, mBio.